{"filings":[{"id":566636,"accession_number":"0001493152-26-024748","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2026-05-21T13:51:20+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Jupiter Neurosciences announces $2M registered direct offering of 7.1M shares at $0.28/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["7,142,858 shares sold at $0.28 per share for gross proceeds of ~$2.0M.","D. Boral Capital LLC is acting as exclusive placement agent.","Closing expected on May 21, 2026, subject to customary conditions.","Shares offered under effective S-3 shelf registration (File No. 333-295085)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":538876,"accession_number":"0001493152-26-024547","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2026-05-20T13:45:15+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Jupiter Neurosciences signs $3.33M non-binding term sheet for exclusive U.S. rights to ALA-002 MDMA","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront consideration $3.33M ($1.5M cash + $1.83M JUNS stock with 120-day lock-up); $600K escrow deposited.","Development milestones: $3.33M upon Phase 3 initiation and $20M on FDA approval.","Commercialization milestones up to $93.33M at net sales thresholds of $333M, $1B, $2B; plus perpetual 3% royalty.","90-day exclusivity period; definitive agreement target within 90 days; reverse termination fee of $600K if not executed.","Deal follows President Trump's April 18, 2026 Executive Order on psychedelic medicine; ALA-002 is an FDA-designated NCE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107155,"accession_number":"0001493152-26-008344","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["3.01","7.01"],"status":"ready","headline":"Jupiter Neurosciences receives Nasdaq deficiency notices for bid price and market value","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Two Nasdaq deficiency notices received Feb 26, 2026: bid price <$1.00 for 30 consecutive days.","Market value of listed securities (MVLS) <$35M for 30 consecutive days; both have 180-day cure period to Aug 25, 2026.","To regain bid price compliance, stock must close ≥$1.00 for 10+ consecutive business days.","Company may consider reverse stock split; trading unaffected for now under ticker JUNS.","Failure to cure may lead to delisting; Company can appeal to a hearings panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107154,"accession_number":"0001493152-26-007624","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Jupiter Neurosciences extends payment start on $6M Yorkville convertible notes to April 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Omnibus Amendment signed Feb 20, 2026 with Yorkville to revise monthly payment terms.","First installment payment pushed to April 1, 2026, a ~3-month extension from original schedule.","Payment calculation changed to a variable schedule as set forth in the amendment.","Company retains option to satisfy installments via cash, Advance Repayment, or combination.","No change to the aggregate $6.0M principal of the convertible notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123493,"accession_number":"0001493152-25-029124","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Jupiter Neurosciences draws $1.86M second tranche from Yorkville SEPA; stockholder approval obtained","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second Pre-Paid Advance closing on Dec 23, 2025: $1,860,000 disbursed to Jupiter Neurosciences.","Issuance of convertible promissory note to Yorkville in exchange for the funds.","Stockholders approved issuance of shares exceeding 19.99% at annual meeting on Dec 19, 2025.","Registration statement on Form S-1 declared effective Dec 11, enabling resale of shares under SEPA.","Company retains right to direct Yorkville to purchase additional shares up to 100% of 5-day average daily trading volume."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123492,"accession_number":"0001493152-25-028789","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Jupiter Neurosciences shareholders approve 4x increase in authorized shares to 500M and new equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 125M to 500M shares via amendment approved by 20.2M votes for, 4.5M against.","2025 Equity Incentive Plan approved, authorizing 5,250,000 shares for future equity awards.","Potential issuance of up to $20M of stock to Yorkville under SEPA (including convertible notes) approved with 20.1M for, 24.7K against.","Seven director nominees elected; Christer Rosén, Marshall Hayward, Alison Silva, Nicholas Hemmerly, Julie Kampf, Allison Brady, Holger Weis.","Cherry Bekaert ratified as independent auditor for FY2025 with 24.6M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123490,"accession_number":"0001493152-25-024454","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K/A","filed_at":"2025-11-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Jupiter Neurosciences amends SEPA with Yorkville, correcting outstanding shares to 34.3M and Exchange Cap to 6.86M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrects outstanding shares as of October 24, 2025 from 34,833,083 to 34,294,446.","Corrects Exchange Cap (max shares issuable without stockholder approval) from 7,180,504 to 6,855,459.","SEPA with Yorkville allows up to $20M stock sales; Yorkville advanced $3.72M for first convertible note (principal $4M, 7% OID).","Stockholder meeting scheduled for December 19, 2025 to seek approval to exceed Exchange Cap for additional issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123491,"accession_number":"0001493152-25-019783","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Jupiter Neurosciences secures up to $20M flexible financing from Yorkville; $4M funded at signing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $4M pre-paid advance funded via convertible note with $1.50 fixed conversion price and 7% OID.","Additional $2M pre-paid advance contingent on registration statement and stockholder approval; total $6M pre-paid.","Up to $14M available under SEPA over 24 months subject to conditions; proceeds to fund Phase 2 Parkinson's trial and Nugevia growth.","Yorkville receives 131,909 commitment shares and $25K structuring fee; issuance subject to 19.99% Exchange Cap unless stockholder approval obtained.","Convertible notes bear 8% interest, mature Oct 24, 2026; repayment via cash or advance notices under SEPA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140168,"accession_number":"0001641172-25-018619","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jupiter Neurosciences regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Nasdaq confirmed compliance on July 9, 2025 after closing bid price ≥ $1.00 for 13 consecutive days (June 18 – July 8, 2025).","Company had been notified of deficiency on March 21, 2025 with a 180-day cure period ending September 17, 2025.","Nasdaq considers the matter closed; common stock (JUNS) continues listing on Nasdaq Capital Market.","Jupiter is a clinical-stage pharma developing JOTROL resveratrol platform for CNS disorders and longevity products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140167,"accession_number":"0001641172-25-018429","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Jupiter Neurosciences grants stock options and conditional cash bonuses to executives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Alison Silva granted 255,320 options; Saleem Elmassri granted 102,128 options; exercise price $1.19, 3-yr vest, 10-yr term.","Cash bonuses subject to company having >$3.5M cash: CEO Christer Rosén $210K, others $45K-$72K, Titan Advisory $72K.","Bonuses approved on July 2, 2025, for officers' roles in IPO success and forgoing prior compensation/debt forgiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157811,"accession_number":"0001641172-25-005506","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Jupiter Neurosciences replaces auditor; prior reports flagged going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Assurance Dimensions resigned as auditor effective April 16, 2025 due to discontinuation of PCAOB practice.","Cherry Bekaert LLP engaged as new independent registered public accounting firm effective same date.","No disagreements or reportable events occurred during the two most recent fiscal years.","AD's audit reports for 2023 and 2024 included a going concern uncertainty note.","The company filed a letter from the resigning auditor confirming agreement with the disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176186,"accession_number":"0001641172-25-000627","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Jupiter Neurosciences receives Nasdaq delisting notice for bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified JUNS on Mar 21, 2025 that bid price closed below $1.00 for 30 consecutive business days through Mar 20, 2025.","Company has 180 calendar days, until Sept 17, 2025, to regain compliance by closing at $1.00 or higher for 10 consecutive days.","No immediate impact on listing; stock continues trading on Nasdaq; company may consider options to cure the deficiency.","If compliance not regained by Sept 17, JUNS may be eligible for additional time or face delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193085,"accession_number":"0001493152-24-050881","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Jupiter Neurosciences revises CFO compensation: monthly fee to Titan increases to $20k for 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Monthly fee for CFO services via Titan Advisory Services LLC set at $20,000 for 2025, up from $5,000 during reduction period.","Fee had been reduced from $25,000 to $20,000 in Jan 2023, then to $5,000 in Oct 2023 pending capital raise.","Titan (through Saleem Elmasri) continues as CFO; eligible for discretionary cash bonuses and equity compensation.","New Scope of Work executed December 17, 2024, effective for calendar year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193084,"accession_number":"0001493152-24-050801","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Jupiter Neurosciences signs $2.3M strategic services deal with Dominant Treasure for SE Asia distribution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One-time payment of $2,300,000 to Dominant Treasure for services to accelerate product development and distribution in Southeast Asia.","Success fee of 5% of any upfront and/or milestone payments if Dominant Treasure helps secure distribution deals in China, Singapore, Malaysia.","Dominant Treasure will also receive 5% of any royalty payments under such distribution agreements.","Agreement has a 36-month term and can be terminated by mutual agreement at any time.","Deal covers China (including Hong Kong), Singapore, and Malaysia market entry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193083,"accession_number":"0001493152-24-048687","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Jupiter Neurosciences closes IPO on Nasdaq, raises $11M gross from 2.75M shares at $4.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 2,750,000 common shares priced at $4.00/sh for gross proceeds of $11M.","Net proceeds to Jupiter are approximately $9.5M after underwriting discounts and expenses.","Shares began trading on Nasdaq Capital Market on Dec 3, 2024 under ticker JUNS.","Proceeds earmarked for Phase II trial of JOTROL in Parkinson's, SE Asia initiatives, R&D, license fees, debt repayment, and working capital.","Dominari Securities acted as lead underwriter; Revere Securities as co-manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193082,"accession_number":"0001493152-24-046734","cik":1679628,"company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Jupiter Neurosciences extends maturity of $1.38M in secured notes by 26 days to Dec 11, 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended Puritan Note ($1,111,111) and Assigned Note ($266,667) maturity from Nov 15 to Dec 11, 2024.","Interest of $9,259 on Puritan Note due Nov 11 paid upon execution; additional $9,259 due by Dec 11.","Interest on Assigned Note payable at maturity unless a Qualified Offering (>$8M) closes earlier.","Qualified Offering defined as a financing raising at least $8M in debt or equity.","Notes retain 10% original issue discount and senior secured status; no other material changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":9520201.230512714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}